Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETAMINE HYDROCHLORIDE vs AMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Induction and maintenance of general anesthesia,Sedation,Analgesic for acute pain,Treatment-resistant depression (off-label),Status epilepticus (off-label)
Induction of general anesthesia,Maintenance of anesthesia (as part of balanced anesthesia),Procedural sedation (off-label),Rapid sequence intubation (RSI) (off-label)
Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
Terminal elimination half-life of ketamine is 2.5–3 hours; norketamine half-life is approximately 4 hours. Context: Prolonged elimination may occur with hepatic impairment or high-dose infusions.
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Hepatic via CYP2B6 and CYP3A4; major metabolite norketamine.
Primarily hepatic via hydrolysis by esterases to inactive metabolites (carboxylic acid and ethanol); also undergoes glucuronidation.
Ketamine is primarily metabolized in the liver via N-demethylation to norketamine. Renal excretion accounts for approximately 90% of the dose, with 4% as unchanged drug, 16% as norketamine, and the remainder as conjugated metabolites. Fecal excretion is minimal (<5%).
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
Approximately 47% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
97–98% bound; Primary binding to albumin; Reduced binding in neonates and hepatic/renal disease.
Volume of distribution is 3–5 L/kg, indicating extensive tissue distribution and accumulation in lipid-rich tissues (e.g., brain, adipose).
Vd: 2.5–4.5 L/kg; Large Vd indicates extensive tissue distribution (highly lipophilic).
Oral: 17–20% (extensive first-pass metabolism); Intranasal: 45–50%; IM: 93%; Rectal: 25–50%; IV: 100%.
IV: 100%; IM: >90%; Rectal: ~50% (variable).
No specific GFR-based dose adjustment is required. Use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of active metabolite norketamine; monitor for prolonged effects.
No adjustment required; pharmacokinetics unchanged in renal impairment.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 25-50% and titrate to effect. Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose by 50-75% and monitor closely.
No specific guidelines; use with caution in severe hepatic impairment due to potential for decreased clearance.
Induction: 1-2 mg/kg IV, 3-4 mg/kg IM. Maintenance: 0.5-1 mg/kg IV or IM as needed. Procedural sedation: 0.5-1 mg/kg IV, may repeat. Continuous infusion: 0.2-0.5 mg/kg/h. Maximum single dose: 2 mg/kg IV, 4 mg/kg IM.
3-5 mg/kg IV bolus for induction in children; lower doses may be sufficient.
Reduce initial dose by 20-50% due to decreased clearance and increased sensitivity. Titrate slowly to effect. Monitor for cardiovascular and cognitive adverse effects closely.
Reduce dose to 0.15-0.3 mg/kg IV bolus due to increased sensitivity and decreased clearance.
None.
None
Emergence reactions (hallucinations, confusion),Hemodynamic instability (hypertension, tachycardia),Increased intracranial pressure,Respiratory depression,Urinary tract toxicity with chronic use
Suppresses adrenal steroidogenesis via reversible inhibition of 11-beta-hydroxylase (cortisol and aldosterone synthesis) – risk of adrenal insufficiency, especially with prolonged infusion or multiple doses,May cause myoclonus (involuntary muscle movements) during induction,Can produce hypotension less frequently than other induction agents, but still possible,Use caution in patients with adrenal suppression, sepsis, or hepatic impairment,May cause pain on injection (use large vein or consider pretreatment)
Hypersensitivity to ketamine,Conditions where elevated blood pressure is dangerous (e.g., aneurysms, uncontrolled hypertension),Severe coronary artery disease,Increased intracranial pressure (relative)
Known hypersensitivity to etomidate or any component of the formulation,Patients with known adrenal insufficiency (relative contraindication due to potential for further suppression)
No significant food interactions; grapefruit juice may increase ketamine levels via CYP3A4 inhibition, but clinical relevance is unclear; avoid alcohol consumption due to additive sedative effects.
None known. However, because etomidate is administered intravenously in a fasting state prior to procedures, food intake is restricted per standard pre-procedural fasting guidelines (typically NPO for 6-8 hours).
Ketamine crosses the placenta. First trimester: Limited human data, animal studies show developmental toxicity at high doses; avoid unless essential. Second/Third trimester: Use only for indicated procedures (e.g., surgical anesthesia, procedural sedation) as maternal hypoxia may risk fetus; potential for neonatal respiratory depression if used near delivery. Neonatal effects: Possible altered neurodevelopment; consider risk-benefit.
Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: May cause fetal CNS depression, hypotonia, and respiratory depression with chronic use. Avoid in pregnancy unless benefit outweighs risk.
Ketamine enters breast milk; milk-to-plasma ratio approximately 0.8-1.5. Limited data; low absolute dose (<2% maternal weight-adjusted dose). Caution with repeated high doses; monitor infant for sedation, feeding difficulties. American Academy of Pediatrics: compatible with breastfeeding after single doses.
Excreted in breast milk; M/P ratio 0.5-0.8. Potential for infant sedation and respiratory depression. Caution advised; monitor infant for drowsiness and feeding difficulties. Consider alternative therapies.
Pregnancy may alter pharmacokinetics: increased volume of distribution may require higher initial doses; decreased plasma protein binding may increase free fraction. However, standard dosing guidelines for procedures apply; titrate to effect. Use lowest effective dose due to potential neurotoxicity. Caution with repeated use or long infusions.
No standard dose adjustment recommended; however, increased clearance during pregnancy may necessitate higher doses for efficacy. Monitor therapeutic response and adjust as needed. Avoid use in first trimester if possible.
Ketamine produces dissociative anesthesia with preserved airway reflexes and respiratory drive at sub-anesthetic doses; monitor for emergence reactions (hallucinations, delirium) especially in adults; co-administer a benzodiazepine to reduce psychotomimetic effects; use with caution in patients with hypertension, tachycardia, or increased intracranial pressure; can cause increased secretions, consider an anticholinergic like glycopyrrolate; analgesic doses are sub-dissociative (0.1-0.5 mg/kg IV); contraindicated in patients with severe coronary artery disease or recent cerebrovascular accident.
Amidate (etomidate) is an ultra-short acting non-barbiturate hypnotic used for induction of anesthesia and for procedural sedation. Key pearls: (1) Single dose causes adrenal suppression via 11β-hydroxylase inhibition; avoid continuous infusion or repeated doses. (2) Preferred for hemodynamically unstable patients due to minimal cardiovascular depression. (3) High incidence of myoclonus and pain on injection; pretreat with opioid or benzodiazepine to reduce myoclonus. (4) Contraindicated in porphyria. (5) Rapid onset (30-60 sec) and short duration (3-5 min) limit use to induction only.
You may feel detached from your body or have unusual dreams during recovery; this is normal and temporary.,Do not drive or operate machinery for 24 hours after receiving ketamine.,Avoid alcohol and other sedatives for at least 24 hours after treatment.,Report any hallucinations, confusion, or difficulty breathing to your healthcare provider immediately.,For nasal spray (esketamine), follow instructions for administration and avoid eating or drinking for 30 minutes after use.
This medication is given only by a healthcare professional in a hospital or clinic setting.,You may experience involuntary muscle movements (myoclonus) or pain at the injection site.,Tell your doctor if you have adrenal gland problems, porphyria, or if you are pregnant or breastfeeding.,The effects are short-lived; you will be monitored closely during and after administration.,Do not drive or operate machinery for at least 24 hours after receiving this medication.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"The combination of ketamine and diamorphine can lead to additive central nervous system (CNS) depression and respiratory depression, increasing the risk of hypoxia, sedation, and respiratory arrest. Ketamine, an NMDA receptor antagonist, enhances opioid-induced analgesia but also potentiates the adverse effects of diamorphine, including hypotension and bradycardia. Patients may experience profound sedation, confusion, and cardiovascular instability, particularly at higher doses or in opioid-naive individuals."
"Ketamine, an NMDA receptor antagonist, may inhibit cytochrome P450 3A4 (CYP3A4) activity, which is responsible for the 25-hydroxylation of cholecalciferol (vitamin D3) to calcidiol (25-hydroxyvitamin D). This inhibition can reduce the conversion of cholecalciferol to its active form, potentially leading to decreased vitamin D levels and impaired calcium homeostasis. Clinically, this may increase the risk of vitamin D deficiency, contributing to bone demineralization, hypocalcemia, or secondary hyperparathyroidism in patients receiving long-term or high-dose ketamine therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETAMINE HYDROCHLORIDE vs AMIDATE, answered by our medical review team.
KETAMINE HYDROCHLORIDE is a General Anesthetic that works by Noncompetitive NMDA receptor antagonist; also interacts with opioid receptors, monoaminergic receptors, and voltage-gated calcium channels.. AMIDATE is a General Anesthetic that works by AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETAMINE HYDROCHLORIDE and AMIDATE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETAMINE HYDROCHLORIDE is: Induction: 1-2 mg/kg IV, 0.5-1 mg/kg/min IV infusion for maintenance. Dissociative sedation: 1-1.5 mg/kg IV or 3-4 mg/kg IM. Pain management: 0.1-0.5 mg/kg IV bolus followed by 0.1-0.4 mg/kg/h IV infusion.. The standard adult dose of AMIDATE is: 0.2-0.6 mg/kg IV bolus for induction of anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETAMINE HYDROCHLORIDE and AMIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETAMINE HYDROCHLORIDE is classified as Category C. Ketamine crosses the placenta. First trimester: Limited human data, animal studies show developmental toxicity at high doses; avoid unless essential. Second/Third trimester: Use on. AMIDATE is classified as Category C. Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.